Skip to content

Caris Life Sciences, Inc.

CAI· NasdaqCore metricsCIK 2019410

Medical laboratories28 peers

Last sale
Nov 12, 2026 · -2.16%
Market cap
$6.87B
286.78M shares
Filings
134
$275.36M
Q3 2026+97.0% FY25 yoy
$15.25M
Q3 2026N/M FY25 yoy
$19.32M
Q3 2026N/M FY25 yoy
-$10.78M
Q3 2026derivedN/M FY25 yoy
$0.05
Q3 2026N/M FY25 yoy
$819.90M
Q1 2026+1,145.2% FY25 yoy
$6.87B
71.5×
6.6×
10.7×
0.42%
—

Twelve months to Sep 30, 2026 · derived

Price

$23.964.77%$1.20past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$812.03MFY 2025
$812.03M0FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$812,033,000reported
FY 20242024-12-31$412,260,000reported
FY 20232023-12-31$306,128,000reported

Capital returns

Dividends and buybacks · FY2023 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$113.00K$113.00K—282.58M sh+674.1%0.2%
FY2024—$0.00$0.00—36.50M sh——
FY2023—$0.00$0.00————

Segments

Revenue by Geography, FY2023 to FY2025FY2023United States · FY2023 · $293.41MInternational · FY2023 · $12.72MFY2024United States · FY2024 · $401.84MInternational · FY2024 · $10.42MFY2025United States · FY2025 · $801.39MInternational · FY2025 · $10.64M
LineFY2025ShareChange
United States$801.39M99%+99.4%
International$10.64M1.3%+2.1%
Total$812.03M

From the 10-K filed Mar 3, 2026CAI

Medical laboratories

Caris Life Sciences, Inc. is the 7th largest of the 29 covered companies the SEC files under this code, by revenue. SIC 8071

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Caris Life Sciences, Inc. · CIK 2019410 · Engraved from SEC EDGAR